



(12) Translation of
European patent specification

(11) NO/EP 3377484 B1

NORWAY

(19) NO

(51) Int Cl.

C07D 403/12 (2006.01)

A61K 31/4418 (2006.01)

A61K 31/505 (2006.01)

A61K 31/506 (2006.01)

A61K 31/513 (2006.01)

A61K 31/5377 (2006.01)

A61K 31/55 (2006.01)

A61P 25/28 (2006.01)

C07D 401/04 (2006.01)

C07D 401/14 (2006.01)

C07D 403/14 (2006.01)

C07D 405/14 (2006.01)

C07D 413/12 (2006.01)

C07D 413/14 (2006.01)

C07D 495/04 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2024.01.15
(80)	Date of The European Patent Office Publication of the Granted Patent	2023.09.06
(86)	European Application Nr.	16805251.2
(86)	European Filing Date	2016.11.16
(87)	The European Application's Publication Date	2018.09.26
(30)	Priority	2015.11.17, US, 201562256199 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Merck Patent GmbH, Frankfurter Strasse 250, 64293 Darmstadt, Tyskland
(72)	Inventor	DELLOVADE, Tammy, 132 Hartwell Road, Carlisle, MA 01741, USA
(74)	Agent or Attorney	ZACCO NORWAY AS, Postboks 488, 0213 OSLO, Norge

(54)	Title	METHODS FOR TREATING MULTIPLE SCLEROSIS USING PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY
(56)	References Cited:	WO-A1-2014/011568, WO-A2-2014/093230, WO-A1-2005/095400, WO-A1-2015/042077, WO-A2-98/24782, WO-A1-2009/055418, WO-A2-2008/039218, WO-A1-2014/163161 WO-A1-2006/136442, WO-A2-2012/170976 JOANNA FONG ET AL: "Neurodegeneration and Neuroprotective Agents in Multiple Sclerosis", RECENT PATENTS ON CNS DRUG DISCOVERY, vol. 3, no. 3, 1 November 2008 (2008-11- 01), pages 153-165, XP055340245, NL ISSN: 1574-8898, DOI: 10.2174/157488908786242498 HEIKO SIC ET AL: "Sphingosine-1-phosphate receptors control B-cell migration through signaling components associated with primary immunodeficiencies, chronic lymphocytic leukemia, and multiple sclerosis", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 134, no. 2, 1 August 2014 (2014-08-01), pages 420-428.e15, XP055340172, AMSTERDAM, NL ISSN: 0091-6749, DOI: 10.1016/j.jaci.2014.01.037

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. En terapeutisk effektiv mengde av en forbindelse, hvor forbindelsen er valgt fra: N-[(1-akryloylpiperidin-4-yl)metyl]-5-(4-fenoksyfenyl)pyrimidin-4,6-diamin, og 1-(4-(((6-amino-5-(4-fenoksyfenyl)pyrimidin-4-yl)amino)metyl)-4-fluor-
5 piperidin-1-yl)prop-2-en-1-on, og farmasøytisk anvendbare salter, tautomerer og stereoisomerer derav, inkludert blandinger hver derav i alle forhold, for anvendelse ved behandling eller forebygging av multipel sklerose.
2. Forbindelsen for anvendelse i henhold til krav 1 hvor forbindelsen er N-[(1-
10 akryloylpiperidin-4-yl)metyl]-5-(4-fenoksyfenyl)pyrimidin-4,6-diamin, og farmasøytisk anvendbare salter, tautomerer og stereoisomerer derav, inkludert blandinger derav i alle forhold.
3. Forbindelsen for anvendelse i henhold til krav 1 hvor forbindelsen er 1-(4-
15 (((6-amino-5-(4-fenoksyfenyl)pyrimidin-4-yl)amino)metyl)-4-fluorpiperidin-1-yl)prop-2-en-1-on, og farmasøytisk anvendbare salter, tautomerer og stereoisomerer derav, inkludert blandinger derav i alle forhold.
4. Forbindelsen for anvendelse i henhold til et hvilket som helst av krav 1-3,
20 hvor multipel sklerosen (MS) er valgt fra residiverende multipel sklerose (RMS), residiverende-remitterende multipel sklerose (RRMS), progressiv multipel sklerose (PMS), sekundær-progressiv multipel sklerose (SPMS), primær-progressiv multipel sklerose (PPMS), og progressiv-residiverende multipel sklerose (PRMS).